#cancer-associated-VTE #venous-thromboembolism #anticoagulation #cardio-oncology #thrombosis

Cancer-Associated VTE

Definition

Cancer-associated venous thromboembolism (VTE) — encompassing DVT, pulmonary embolism, superficial thrombophlebitis, catheter-associated thrombosis, and iliocaval thrombosis — is the most common cardiovascular complication of malignancy. Cancer itself acts as a pro-thrombotic state through multiple mechanisms (activation of the coagulation cascade, endothelial injury, platelet activation, impaired fibrinolysis), and many cancer therapies amplify this risk further.

Key Concepts

Epidemiology

Cancer increases VTE risk 7–8-fold vs. the general population. (sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high)
Hematological malignancies: 28× increased odds of VTE; lung and GI tumors: >20×. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Annual incidence: 0.5% in cancer vs. 0.1% in general population; cancer accounts for ~20% of total VTE burden. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Risk highest in first year after cancer diagnosis (15-fold); increases with metastatic spread (2-year cumulative incidence rises from localized → regional → remote disease). (sources/cardio-oncology-vascular-metabolic-aha-2019)
Despite stable background VTE rates, cancer-associated VTE incidence is increasing over time. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Cancer-VTE clot burden is higher: bilateral lower limb DVT, iliocaval thrombosis, upper limb DVT all more common vs. non-cancer VTE. (sources/cardio-oncology-vascular-metabolic-aha-2019)

Prognosis

VTE in cancer is a poor prognostic sign: mortality 5–6× higher vs. non-cancer VTE. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Within cancer-only populations, VTE increases mortality 1.6–4.2-fold. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Patients with cancer-associated VTE have increased bleeding risk AND increased VTE recurrence risk. (sources/cardio-oncology-vascular-metabolic-aha-2019)

Recurrence Risk — Ottawa Score

Ottawa Score predicts recurrent VTE in cancer-associated thrombosis: (sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high)

Variable	Points
Female	+1
Lung cancer	+1
Breast cancer	−1
TNM stage I	−2
Prior VTE	+1

Score ≤0 = Low risk (<4.5% recurrence); Score ≥1 = High risk (~19% recurrence)
Performance: 100% sensitivity, 98.1% NPV, negative likelihood ratio 0.16
Validated in 2 RCTs of anticoagulation in cancer-associated VTE
VTE recurrence rate: ~21% at 1 year in cancer vs. 7% in non-cancer VTE; relative risk 2.4× for DVT and 2.0× for PE recurrence (RIETE registry, n~19,000). (sources/cardio-oncology-vascular-metabolic-aha-2019)

Anticoagulation Strategy

Duration

Extended/indefinite anticoagulation (no scheduled stop date) recommended even with high bleeding risk — ACCP guidelines (because recurrence risk is consistently elevated). (sources/cardio-oncology-vascular-metabolic-aha-2019)
No recommendation for routine VTE prophylaxis in cancer outpatients, except multiple myeloma patients on thalidomide/lenalidomide-based regimens (risk-stratified prophylaxis required).

Drug Choice

LMWH preferred over VKA — two pivotal trials showed superiority for recurrent VTE prevention: (sources/cardio-oncology-vascular-metabolic-aha-2019)
- Dalteparin (CLOT trial): superior to warfarin for recurrent VTE
- Enoxaparin (LITE trial): superior to warfarin for recurrent VTE
- Tinzaparin: trended toward benefit, did not reach statistical significance
- Limitations of LMWH: cost, injections, no easy reversal agent

Emerging DOAC Evidence (2019 Data)

Edoxaban vs. dalteparin (n=1,050; 6–12 months): Primary outcome (recurrent VTE or major bleeding) 12.8% vs. 13.5% — non-inferior (P=0.006 for noninferiority). (sources/cardio-oncology-vascular-metabolic-aha-2019)
Rivaroxaban vs. dalteparin (pilot): VTE recurrence HR 0.43 (CI 0.19–0.99) — fewer recurrences; but clinically relevant non-major bleeding HR 3.76 (CI 1.63–8.69) — more bleeding. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Apixaban vs. dalteparin (abstract presentation): VTE recurrence 3.4% vs. 14.1% (HR 0.26, CI 0.09–0.80; P=0.018) with superior QoL and very low bleeding rates. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Conclusion (2019 view): DOACs likely to become standard for cancer-associated VTE, but caveats apply — renal/liver dysfunction effects on dosing, drug-drug interactions (P-glycoprotein and CYP3A4 substrates), reversibility of anticoagulation

Extended Duration Anticoagulation — API-CAT Trial (NEJM 2025)

The API-CAT trial is the first double-blind RCT specifically addressing which dose of apixaban to use during the extended treatment phase (>6 months) in active cancer patients with DVT or PE. (sources/reduced-apixaban-apicat-nejm-2025, rating: very high)

Design: N=1,766; 121 centers; 11 countries; randomized 1:1 to apixaban 2.5 mg BID vs 5.0 mg BID × 12 months; enrolled after completing ≥6 months of anticoagulation without symptomatic recurrence
Eligibility: Active cancer + proximal DVT or symptomatic/incidental PE; 75.5% PE index event; median time since index VTE 8.0 months; 92.6% ECOG 0–1
Cancer sites: Breast 22.7%, colorectal 15.2%, gynecologic 12.1%, lung 11.3%
Primary efficacy outcome (recurrent VTE): 2.1% (reduced) vs 2.8% (full); SHR 0.76 (95% CI 0.41–1.41; P=0.001 for noninferiority; margin 2.00) — noninferiority confirmed ✓
Key secondary outcome (clinically relevant bleeding): 12.1% vs 15.6%; SHR 0.75 (95% CI 0.58–0.97; P=0.03 superiority) — reduced dose superior ✓
Major bleeding: 2.9% vs 4.3% (SHR 0.66; CI 0.40–1.10; NS but directionally consistent); 2 fatal bleeds in each group
All-cause mortality: 17.7% vs 19.6% (HR 0.96; NS); ~83% cancer-related deaths
Net clinical benefit (VTE + major bleed + death): 19.9% vs 22.1% (HR 0.96; NS)
Clinical implication: Reduced-dose apixaban (2.5 mg BID) is the preferred extended-duration anticoagulation strategy in cancer-associated VTE beyond 6 months — maintains VTE protection and reduces bleeding
VTE recurrence rates were lower than anticipated (vs projected 4%/year), possibly due to inclusion of incidental VTE events and favorable cancer subtypes (breast cancer heavily represented)

Immunomodulator (Thalidomide/Lenalidomide) VTE Prophylaxis

3-tier risk stratification for thromboprophylaxis: (sources/cardio-oncology-vascular-metabolic-aha-2019)
- Low risk (single-agent thalidomide/analog, no additional risk factors): no prophylaxis required (<5%)
- Standard risk (no/1 risk factor, not on multiagent chemo or high-dose dexamethasone): aspirin 81 mg/day (up to 20% risk)
- High risk (≥2 risk factors OR multiagent chemo OR high-dose dexamethasone): LMWH or warfarin

Bevacizumab (VEGF-A antibody): Highest VTE incidence among VEGF inhibitors — ~12% of patients; nearly half are high-grade. (sources/cardio-oncology-vascular-metabolic-aha-2019)
VEGF receptor TKIs (sunitinib, sorafenib, etc.): VTE incidence 2–6%. (sources/cardio-oncology-vascular-metabolic-aha-2019)
IMiDs (thalidomide, lenalidomide): Predominantly venous events; risk amplified by concomitant multiagent chemotherapy/dexamethasone. (sources/cardio-oncology-vascular-metabolic-aha-2019)
BCR-ABL TKIs (ponatinib, nilotinib): Arterial ischaemic events dominate; VTE also described. (sources/cardio-oncology-vascular-metabolic-aha-2019)

Contradictions / Open Questions

DOAC data at time of this 2019 statement were from pilot studies and abstract presentations — prospective DOAC cancer-VTE RCTs were pending; subsequent data (Caravaggio, SELECT-D) have since supported DOAC use, but concerns about bleeding with GI/GU cancers persist. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Ottawa Score validated in VTE-treatment RCTs but not in broader oncology populations.
No validated cancer-specific bleeding score exists; HAS-BLED underperforms in cancer patients (does not capture thrombocytopenia or intracranial metastases). See concepts/Cancer-Therapy-Related-CV-Toxicity.
Routine VTE prophylaxis in cancer outpatients is not recommended, but selected high-risk patients (Khorana score ≥2) may benefit — guidelines evolving. (sources/cardio-oncology-vascular-metabolic-aha-2019)
API-CAT: recurrence rates (2.1–2.8%) much lower than the anticipated 4%/year used in power calculations — lower-risk patients (incidental VTE, 22.7% breast cancer) may have been enrolled; whether results generalize to higher-risk populations (GI/GU cancers, hematological malignancies) is unconfirmed. (sources/reduced-apixaban-apicat-nejm-2025)
Optimal duration of extended anticoagulation beyond 24 months remains unknown — API-CAT only covers 12 months of extended treatment; no data exist beyond 2 years from index VTE in a blinded RCT. (sources/reduced-apixaban-apicat-nejm-2025)
Dose during initial 6-month phase vs extended phase: API-CAT enrolled patients who completed standard-dose initial therapy; whether starting with reduced-dose earlier is safe is unknown.
Bleeding with reduced dose (12.1%) remains substantial — absolute 3.5 pp reduction in clinically relevant bleeding is meaningful but high baseline rate highlights ongoing need for bleeding risk stratification tools in cancer patients. (sources/reduced-apixaban-apicat-nejm-2025)

Connections

Related to concepts/Cancer-Therapy-Related-CV-Toxicity
Related to concepts/Cardio-Oncology
Related to concepts/Venous-Thromboembolism-Anticoagulation — non-cancer VTE NOAC evidence (COBRRA, HI-PRO) does NOT apply to cancer-associated VTE; cancer was an exclusion criterion in both trials
Related to concepts/pulmonary-hypertension
Related to sources/cardio-oncology-vascular-metabolic-aha-2019
Related to sources/reduced-apixaban-apicat-nejm-2025